Navigation Links
Odyssey Thera is First to Install Next Generation High-Content Imaging Capability
Date:11/29/2011

SAN RAMON, Calif., Nov. 29, 2011 /PRNewswire/ -- Odyssey Thera, Inc., a technology provider focused on deciphering biologically-relevant pathways in human cells, announced today that it has installed the IN Cell Analyzer 6000, a laser-based confocal imaging platform from GE Healthcare, to advance the world's largest high-content assay capability.

Odyssey Thera applies a systems biology approach to advance knowledge of the complex cellular networks responsible for biologically–relevant pathway activity. The company has advanced proprietary, cell-based technologies including protein-fragment complementation assays (PCAs) that allow protein-protein complexes to be precisely imaged and localized within live cells.

Using PCA and other technologies, Odyssey has created the world's largest high-content assay capability. Fully-integrated hardware, software and IT infrastructure enables very high throughput, creating a unique systems- and chemical-biology platform capable of capturing and analyzing hundreds of thousands of microscopic images per day.

The IN Cell Analyzer 6000 employs a unique optical engine combined with a next generation sCMOS detector to support high-throughput and high-resolution imaging of diverse biological events. In contrast to conventional fixed aperture confocal systems, the proprietary IN Cell Analyzer 6000 optical system features a fully adjustable variable aperture for increased flexibility.

"The IN Cell 6000 is designed for the most demanding high-content cellular applications, including live cell assays, 3D imaging, co-localization studies and imaging of assays with low signal. The choice of GE Healthcare's IN Cell 6000 reflects Odyssey's goal of maintaining our leadership position in highly contextual cellular analysis," said John K. Westwick, Ph.D., President and CEO of Odyssey Thera.

"The Odyssey team will use the IN Cell 6000 for multiple projects, including advancement of partner drug discovery programs and collaborative work with the United States Environmental Protection Agency (EPA), in which methods are being developed to improve detection of environmental toxicants," said Jane E. Lamerdin, Ph.D., Executive Director of R&D at Odyssey Thera.

About Odyssey Thera

Odyssey Thera, Inc. is a privately held biotechnology company based in San Ramon, California. The company is a leading developer of enabling technologies focused on deciphering biologically-relevant pathways in living human cells to improve the process of target and drug discovery and to advance methods for environmental chemical toxicity assessment. Patents owned by Odyssey Thera cover the use of the PCA technology in human cells, live animals, plants, diagnostic and biomarker, bioprocess, biodefense, and environmental applications. To learn more about Odyssey Thera, please visit www.odysseythera.com.

About GE Healthcare

GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform and treat disease, so their patients can live their lives to the fullest. Headquartered in the United Kingdom, GE Healthcare is a $17 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com.


'/>"/>
SOURCE Odyssey Thera, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Stereotaxis Board of Directors Reaffirms Commercialization Plans for Epoch™ and Odyssey™ Product Platforms
2. Stereotaxis Reports Second Quarter Financial Results; Rebalances Investment Around Commercialization of Epoch™ and Odyssey™
3. Odyssey Thera Announces U.S. Patent for Technologies Enabling Protein Interaction Screening and Directed Evolution
4. Odyssey Thera to Participate in Expanded EPA Initiative
5. Stereotaxis Launches the Odyssey Interventional Network for Superior Online Cardiovascular Education and Training
6. Stereotaxis and Siemens Promote Integrated Odyssey(TM) Solutions
7. Odyssey Thera Announces Achievement of Pfizer Drug Candidate Milestones
8. Abbott Expands Agreement with GSK to Include Development of a Companion Diagnostic Test for an Additional Investigational Cancer Immunotherapy Antigen
9. Pain Management Therapeutics Market to 2017 - Price Competition to Intensify Following Patent Expiries of Lyrica and Cymbalta
10. Inspiration Biopharmaceuticals Initiates Second Pivotal Clinical Study of Innovative Hemophilia Therapy OBI-1
11. Takeda Submits New Drug Application in the U.S. for Investigational Type 2 Diabetes Therapy, Fixed-Dose Combination Alogliptin/Metformin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... , Feb. 22, 2017 Henry ... an exclusive distribution agreement with Rijuven, which develops ... diagnostic device to medical practitioners. ... electrocardiogram (ECG) and heart sound signals, transmits real-time ... and offers cloud-based analysis to help physicians provide ...
(Date:2/22/2017)... Calif. , Feb. 22, 2017  Bioness, Inc., ... therapies, today announced the first series of successful StimRouter ... at Radboud University Medical Center (Nijmegen, Netherlands ... ( Cork, Ireland ), and Kliniek Park ... the successful launch continuing, Bioness plans to further support ...
(Date:2/22/2017)... , Feb. 22, 2017 Oncternal Therapeutics, ... for both rare and common malignancies, today announced ... financing. The company intends to use the proceeds ... TK216, and to advance preclinical development of a ... Cirmtuzumab is a first-in-class anti-ROR1 monoclonal antibody being ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... ... newest advanced absorption cannabidiol (CBD) serum, “NANOCALM 300” Microemulsified Hemp Extract. This ... instant absorption from the mouth into the bloodstream. Far outpacing the ...
(Date:2/22/2017)... ... 22, 2017 , ... The Centers for Medicare & Medicaid ... in Delaware, New Jersey, Pennsylvania and West Virginia prepare for and participate in ... Act of 2015 (MACRA). , This technical assistance, authorized and funded under ...
(Date:2/22/2017)... NJ (PRWEB) , ... February 22, 2017 , ... ... healthcare communications company, launched a new media platform connecting healthcare technology professionals and ... will be followed by a quarterly publication starting on March 1, announced Michael ...
(Date:2/22/2017)... ... February 22, 2017 , ... Pet obesity in the U.S. continued ... according to the Association for Pet Obesity Prevention (APOP). During the ninth annual survey, ... such as the benefits of corn and grains, value of raw and organic diets, ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... so many different solutions on the market, it is easy to start feeling ... Premier Locksmith offers a complimentary security consultation. , Home Security Hardware Choices, ...
Breaking Medicine News(10 mins):